Results 61 to 70 of about 719,508 (214)

c-erbB-2 expression in benign and malignant breast disease. [PDF]

open access: yes, 1988
An antibody, 21N, raised against a synthetic peptide from the predicted sequence of the c-erbB-2 protein has been used immunocytochemically in a retrospective study of formalin fixed paraffin embedded breast biopsies.
Gusterson, BA   +17 more
core   +1 more source

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report

open access: yesJournal of International Medical Research, 2020
The ErbB family is composed of four cell membrane receptors: ErbB-1 (epidermal growth factor receptor or human epidermal growth factor receptor [HER]1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4).
Mengyao Sun   +7 more
doaj   +1 more source

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors

open access: yesCell Reports Medicine, 2021
Summary: Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR binding. Tumor selectivity is crucial because on-
Paris Kosti   +14 more
doaj   +1 more source

Drug Repurposing for Treating NCOR‐Related Intellectual Disability

open access: yesAdvanced Science, EarlyView.
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong   +15 more
wiley   +1 more source

ErbB receptors profile in non-selected patients with endometrial cancer

open access: yes, 2019
ErbB receptors are trans-membrane glycoproteins with tyrosine kinase activity. Especially in cancer, they are implicated in cell proliferation, transformation, angiogenesis, migration and invasion.
Adonakis Georgios   +7 more
core   +1 more source

A Peptide Antagonist of the ErbB1 Receptor Inhibits Receptor Activation, Tumor Cell Growth and Migration In Vitro and Xenograft Tumor Growth In Vivo

open access: yesCellular Oncology, 2010
The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in tumorigenesis and cancer disease progression, and therefore has become an attractive target for structure-based drug design.
Ruodan Xu   +4 more
doaj   +1 more source

Fc‐Dependent Targeting of the GAS6–MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21

open access: yesAdvanced Science, EarlyView.
EGFR mutations drive a substantial fraction of non‐small cell lung cancers (NSCLC) and are effectively targeted by tyrosine kinase inhibitors (TKIs), including osimertinib. However, resistance inevitably develops through secondary mutations and compensatory receptor activation, including the GAS6 receptor MERTK.
Suvendu Giri   +28 more
wiley   +1 more source

Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors [PDF]

open access: yesClinical Cancer Research, 2009
AbstractPurpose: This study aimed to investigate the expression of the ErbB family of receptor tyrosine kinases in pulmonary typical carcinoid and atypical carcinoid tumors and to understand the role of epidermal growth factor receptor (EGFR) signaling in pulmonary carcinoid tumor proliferation.Experimental Design: Surgically resected typical carcinoid
Otis B, Rickman   +6 more
openaire   +2 more sources

Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer

open access: yesAdvanced Science, EarlyView.
Solid tumor hypoxia severely compromises natural killer cell function. This study demonstrates that hypoxic preconditioning preserves NK cell antitumor activity by limiting excessive stress ‐MAPK signaling and promoting mitochondrial metabolic fitness.
Dian Zhuang   +12 more
wiley   +1 more source

Effects of Dietary Mannan Oligosaccharides on Growth, Disease Resistance, and Gut Microbiota in Zebrafish

open access: yesAnimal Research and One Health, EarlyView.
Supplementation with mannan oligosaccharides (MOS) enhances growth, disease resistance, antioxidant capacity, and gut microbiota diversity while suppressing inflammation, apoptosis, and strengthening intestinal barrier integrity in zebrafish challenged with LPS or DSS.
Zhiyuan Lu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy